Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Operating Expenses (2025)

NewAmsterdam Pharma's Other Operating Expenses history spans 1 years, with the latest figure at -$1000.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses changed N/A year-over-year to -$1000.0; the TTM value through Dec 2025 reached -$1000.0, changed N/A, while the annual FY2022 figure was $61.8 million, N/A changed from the prior year.
  • Other Operating Expenses for Q3 2025 was -$1000.0 at NewAmsterdam Pharma.
  • Across five years, Other Operating Expenses topped out at -$1000.0 in Q3 2025 and bottomed at -$1000.0 in Q3 2025.